Pulmonary hypertension: reasonable selection of specific therapy
Pulmonary hypertension is characterized with persistent increase in pulmonary vascular resistance leading to progressive worsening of right ventricular failure and death. The basis for pulmonary arterial hypertension is structural changes in pulmonary arteries and arterioles caused by endothelial dy...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IP Morozov P.V.
2018-03-01
|
| Series: | Системные гипертензии |
| Subjects: | |
| Online Access: | https://syst-hypertension.ru/2075-082X/article/viewFile/29597/pdf |
| _version_ | 1828444180958937088 |
|---|---|
| author | N A Karoli S I Sazhnova A P Rebrov |
| author_facet | N A Karoli S I Sazhnova A P Rebrov |
| author_sort | N A Karoli |
| collection | DOAJ |
| description | Pulmonary hypertension is characterized with persistent increase in pulmonary vascular resistance leading to progressive worsening of right ventricular failure and death. The basis for pulmonary arterial hypertension is structural changes in pulmonary arteries and arterioles caused by endothelial dysfunction. Endothelin-1 is the main pathogenic trigger of pulmonary hypertension and potential target for therapeutic exposure. The efficacy of endothelin receptor antagonists is proved in various preclinical and clinical studies. In patients with pulmonary arterial hypertension, the efficacy of dual and selective endothelin receptor antagonists is comparable despite the varied activity against various receptors. Bosentan is the most widely used pulmonary vasodilator which improves exercise tolerance and decelerates disease progression. |
| first_indexed | 2024-12-10T21:39:38Z |
| format | Article |
| id | doaj.art-4370ee1e93ed495882c1f2827ee4f44a |
| institution | Directory Open Access Journal |
| issn | 2075-082X 2542-2189 |
| language | Russian |
| last_indexed | 2024-12-10T21:39:38Z |
| publishDate | 2018-03-01 |
| publisher | IP Morozov P.V. |
| record_format | Article |
| series | Системные гипертензии |
| spelling | doaj.art-4370ee1e93ed495882c1f2827ee4f44a2022-12-22T01:32:32ZrusIP Morozov P.V.Системные гипертензии2075-082X2542-21892018-03-01151455010.26442/2075-082X_15.1.45-5026625Pulmonary hypertension: reasonable selection of specific therapyN A Karoli0S I Sazhnova1A P Rebrov2V.I.Razumovsky Saratov State Medical University of the Ministry of Health of the Russian FederationV.I.Razumovsky Saratov State Medical University of the Ministry of Health of the Russian FederationV.I.Razumovsky Saratov State Medical University of the Ministry of Health of the Russian FederationPulmonary hypertension is characterized with persistent increase in pulmonary vascular resistance leading to progressive worsening of right ventricular failure and death. The basis for pulmonary arterial hypertension is structural changes in pulmonary arteries and arterioles caused by endothelial dysfunction. Endothelin-1 is the main pathogenic trigger of pulmonary hypertension and potential target for therapeutic exposure. The efficacy of endothelin receptor antagonists is proved in various preclinical and clinical studies. In patients with pulmonary arterial hypertension, the efficacy of dual and selective endothelin receptor antagonists is comparable despite the varied activity against various receptors. Bosentan is the most widely used pulmonary vasodilator which improves exercise tolerance and decelerates disease progression.https://syst-hypertension.ru/2075-082X/article/viewFile/29597/pdfpulmonary arterial hypertensionendothelin receptor antagonistsbosentanambrisentanmacitentan |
| spellingShingle | N A Karoli S I Sazhnova A P Rebrov Pulmonary hypertension: reasonable selection of specific therapy Системные гипертензии pulmonary arterial hypertension endothelin receptor antagonists bosentan ambrisentan macitentan |
| title | Pulmonary hypertension: reasonable selection of specific therapy |
| title_full | Pulmonary hypertension: reasonable selection of specific therapy |
| title_fullStr | Pulmonary hypertension: reasonable selection of specific therapy |
| title_full_unstemmed | Pulmonary hypertension: reasonable selection of specific therapy |
| title_short | Pulmonary hypertension: reasonable selection of specific therapy |
| title_sort | pulmonary hypertension reasonable selection of specific therapy |
| topic | pulmonary arterial hypertension endothelin receptor antagonists bosentan ambrisentan macitentan |
| url | https://syst-hypertension.ru/2075-082X/article/viewFile/29597/pdf |
| work_keys_str_mv | AT nakaroli pulmonaryhypertensionreasonableselectionofspecifictherapy AT sisazhnova pulmonaryhypertensionreasonableselectionofspecifictherapy AT aprebrov pulmonaryhypertensionreasonableselectionofspecifictherapy |